Crossmark

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Published Online: 2018-03-01

Published Print: 2018-12

Authors

Nakajima, Hiroki

Okada, Sadanori

Mohri, Takako

Kanda, Eiichiro

Inaba, Naoyuki

Hirasawa, Yoko

Seino, Hiroaki

Kuroda, Hisamoto

Hiyoshi, Toru

Niiya, Tetsuji

Ishii, Hitoshi
Clinical Trials ^BETA

Clinical trials referenced in this document:

umin000016304 at UMIN Japan

Documents that mention this clinical trial

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)
https://doi.org/10.1186/s13098-018-0313-x
Funding

Funding for this research was provided by:

AstraZeneca K.K. (ESR-14-10311)

Ono Pharmaceutical Co., Ltd. (ESR-14-10311)
License Information

Text and Data Mining valid from 2018-03-01

Version of Record valid from 2018-03-01
More Information

Article History

Received: 12 December 2017

Accepted: 15 February 2018

First Online: 1 March 2018

Document is current